Home Infusion Therapy Market Size | Statistics Report 2028

[Research Report] The home infusion therapy market is expected to grow from US$ 21,765.95 million in 2022 to US$ 35,696.05 million by 2028; it is estimated to record a CAGR of 8.6% from 2022 to 2028.

Market Insights and Analyst View:

Home infusion therapy involves the intravenous or subcutaneous administration of drugs or biologicals to an individual at home. The components needed to perform home infusion include the drug (antivirals, immune globulin), equipment (a pump), and supplies (tubing and catheters). The home infusion process typically requires coordination among multiple entities, including patients, physicians, hospital discharge planners, health plans, home infusion pharmacies, and, if applicable, home health agencies. The increasing incidences of chronic disorders and rising geriatric population are boosting the home infusion therapy market growth.

Growth Drivers and Challenges:

Chronic disorders such as cardiovascular, nutritional, and gastrointestinal disorders, rheumatoid arthritis, and neurological disorders affect the overall quality of life. According to the World Health Organization (WHO), over 50% of the global population is estimated to suffer from at least one chronic disease. The Centers for Disease Control and Prevention (CDC) stated that 6 out of 10 people in the US suffered from at least one chronic disease in 2019. According to the “Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study,” a large-scale multinational study published in 2021, ~40% of 73,076 adults surveyed from 33 countries in the world were suffering from a functional gastrointestinal disorder (GFID). Age-related gastrointestinal problems are more common in the elderly population, aged 64 and above. Per the study titled “Gastrointestinal problem among Indian adults: Evidence from Longitudinal Aging Study in India”, published in 2022, self-reported gastrointestinal disorders prevalence was reported at ~18%. The study also mentions that varying rates of gastrointestinal problems have been observed across the world, ranging from 14% in Iran to 54% in some western countries.

Cardiovascular diseases (CVDs), especially the cases associated with hectic lifestyles, are a significant cause of mortality globally. According to the International Diabetes Federation (IDF), 537 million people worldwide, aged 20–79, had diabetes in 2021, and the number is estimated to rise to 783 million by 2045. Additionally, diabetes was the cause of 6.7 million deaths worldwide in 2021. According to the Neurological Alliance, ~14.7 million neurological cases were registered in 2019, with at least 1 in 6 people suffering from 1 or more neurological conditions.

Aging can cause a consistent loss of physiological integrity, resulting in a reduction in functionality and an increased risk of mortality. The degradation of body function is a key risk factor for contracting the majority of chronic diseases, including diabetes, CVD, and neurological diseases, among elderly patients. According to the Global Ageing Survey 2019, the frequency of a person aged 65 or above is likely to increase from 1 in every 11 inhabitants in 2019 to 1 in every 6 inhabitants by 2025. As per the US Census Bureau, the number of Americans with age 65 and above is anticipated to double from 46 million in 2016 to over 98 million by 2060, and the share of the elderly population in the global population will increase from 15% to ~24% in the same period. Moreover, except in Africa, the pace of aging will be high in all regions, having nearly a quarter or more of their population aged 60 and above by 2050. Thus, the rising incidence of chronic conditions, coupled with the growing geriatric population, drives the growth of the home infusion therapy market.

However, In the last few years, medical agencies have received many reports of adverse events involving infusion pumps which led to product recalls. The main reason for infusion pump product recalls are software-related problems, user interface issues, and mechanical and electrical failures. For instance, In April 2022, Smiths Medical recalled more than 118,000 Medfusion syringe infusion pumps (model-3500 and 4000) due to software malfunction, causing serious patient harm or death because of under or over-infusion, or delayed delivery of critical medications to patients. It caused about seven serious injuries and one death. Similarly, In December 2020, the FDA announced the Class 1 recall of more than half a million Baxter Sigma infusion pumps due to a defective alarm that caused 3 patient deaths and 51 serious injuries. Thus, the safety concerns associated with home infusion procedures and recalls of infusion pumps hinder the growth of the home infusion therapy market.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Home Infusion Therapy Market: Strategic Insights

Home Infusion Therapy Market

• 
  CAGR (2022 - 2028)

  8.6%
• Market Size 2022
  US$ 21.77 Billion
• Market Size 2028
  US$ 35.7 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• B. Braun Melsungen AG
• Micrel Medical Devices SA
• Baxter International Inc
• Nipro Corp
• Becton Dickinson and Co
• Fresenius Kabi AG
• ICU Medical Inc
• JMS Co Ltd
• Eitan Medical Ltd

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Product

• Infusion Pumps
• Intravenous Sets
• IV Cannulas
• Needleless Connectors

Application

• Anti-Infective
• Endocrinology
• Enteral Nutrition
• Hydration Therapy
• Chemotherapy
• Specialty Pharmaceuticals
• Others

Route of Administration

• Intramuscular
• Subcutaneously
• Epidural

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Report Segmentation and Scope:

The global home infusion therapy market is segmented based on product, application, end user, and geography. Based on product, the home infusion therapy market is segmented into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. The infusion pumps segment is sub-segmented into insulin pumps, elastomeric pumps, and syringe pumps. Based on Application, the home infusion therapy market is segmented into anti-infective, endocrinology, enteral nutrition, specialty pharmaceuticals, hydration therapy, chemotherapy, and others. Based on route of administration, the home infusion therapy market is segmented into intramuscular, subcutaneously, and epidural.

The global home infusion therapy market based on geography is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America)

Segmental Analysis of the Global Home Infusion Therapy Market:

Based on product, the home infusion therapy market is segmented into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. In 2022, the infusion pumps segment accounted for the largest market share. Also, the same segment is anticipated to register the highest CAGR during the forecast period as infusion pumps are widely used to provide nutrition and administer medications to patients, including high-risk medications. The market for the infusion pumps segment is sub-segmented into insulin pumps, elastomeric pumps, and syringe pumps. In 2022, the insulin pumps segment accounted for the largest market share.  

Based on application, the home infusion therapy market is segmented into anti-infective, endocrinology, enteral nutrition, specialty pharmaceuticals, hydration therapy, chemotherapy, and others. The anti-infective segment held the largest share of the market in 2022. The endocrinology segment is expected to grow at the highest CAGR. 

Based on route of administration, the home infusion therapy market is segmented into intramuscular, subcutaneously, and epidural. In 2022, the intramuscular segment held the largest share of the home infusion therapy market, and it is also expected to register the highest CAGR. Factors such as rapid onset of the action of the medication with no gastric problems fuels the intramuscular segment growth.

Regional Analysis:

Based on geography, the global home infusion therapy market is segmented into five key regions: North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. In 2022, North America held the largest share of the global home infusion therapy market size, and Asia Pacific is estimated to register the highest CAGR during the forecast period. In North America, the U.S. is the largest market for home infusion therapy.

Asia Pacific is expected to account for the fastest growth in the global home infusion therapy market. China held the largest market share in 2022, and India is expected to register a significant CAGR in the market. The market growth in these countries is attributed to the increasing prevalence of chronic diseases, the rising geriatric population, the growing presence of home infusion therapy providers, and the rising number of government initiatives. For instance, the Chinese government has adopted Healthy China 2030 to facilitate healthcare services within the nation while delivering great benefits worldwide. The population in the country is more prone to infectious, chronic, and acute diseases. China faces a high burden of lung cancer, colorectal cancer, esophageal cancer, heart disease, and diabetes. Healthcare providers often recommend IV-based therapies and drug administration for the treatment of cancer, infections, and other diseases, thus driving the home infusion therapy market growth.

As per the World Health Organization (WHO), China has a high prevalence rate of diabetes, as more than 10% of the total population in China is suffering from diabetes. Also, as per the WHO, by 2040, ~402 million people (28% of the total population) will be over the age of 60. Thus, the rising geriatric population and the growing prevalence of metabolic risk factors are increasing the burden of CVDs and diabetes across the country. This is generating requirements for the application of home infusion therapies for drug administration and IV therapies in China. Further, the growing presence of local key players is boosting the growth of the home infusion therapy market in China. Manufacturers are focusing on expanding their strategic global presence and specialized expertise with exclusive technological capabilities, leading to the expansion of the home infusion therapy market in China. Hence, the rise in the prevalence of diabetes and chronic diseases, the increase in the geriatric population, and the surge in the number of regional players are expected to propel the growth of the home infusion therapy market in China during the forecast period.

Home Infusion Therapy Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the global home infusion therapy market are listed below:

1. In January 2023, Eitan Medical announced the opening of its new manufacturing facility at the company’s headquarters. On-site manufacturing will support Eitan Medical’s production scale of its Pharmaceutical Solutions division. The facility will manufacture the Sorrel wearable drug delivery platform across multiple device configurations, including Sorrel vial- and cartridge-based wearable injectors, pre-filled and pre-loaded in primary containers up to 50ml, as well as small volume on-body injectors.
2. In May 2022, Fresenius Kabi completed the acquisition of Ivenix, a manufacturer of infusion systems. Fresenius Kabi now offers health care professionals in the United States a broad and expanding portfolio of advanced infusion pumps and solutions to meet needs across the continuum of care.
3. In January 2022, ICU Medical Inc announced that it has completed its acquisition of Smiths Medical from Smiths Group plc. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical’s existing businesses, the combined companies create a leading infusion therapy company with estimated pro forma combined revenues of approximately $2.5 billion.
4. In June 2021, Micrel Medical Devices announced the expansion of their global presence with the announcement of a new distribution partnership with Baxter in Australia and New Zealand for the Rythmic PN+, ambulatory Infusion pump for Home Parenteral Nutrition.
5. In June 2021, Micrel Medical and Baxter Healthcare (Baxter) announced an agreement for the distribution of the Micrel Mini Rythmic PN+ infusion pump for Parenteral Nutrition (PN). Micrel Mini Rythmic PN+ is an ambulatory infusion pump supporting patients with Hospital-in-the-Home Parenteral Nutrition. As part of the agreement, Baxter Healthcare will be the sole distributor of the Micrel Mini Rythmic PN+ infusion pump and its accessories across ANZ.

Competitive Landscape and Key Companies:

There are various prominent players operating in the global home infusion therapy market. Some top home infusion companies are B. Braun Melsungen AG, Micrel Medical Devices SA, Baxter International Inc, Nipro Corp, Becton Dickinson and Co, Fresenius Kabi AG, ICU Medical Inc, JMS Co Ltd, Eitan Medical Ltd, and Terumo Corp, among others. These companies focus on various new product developments and geographical expansions. This helps them to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence which allows them to serve a large set of customers. Also, it offers opportunity to increase their market share.